These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 16103970)

  • 1. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
    Vogel RJ
    Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative approaches to pharmaceutical price regulation in the European Union.
    Mrazek MF
    Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reference pricing and firms' pricing strategies.
    Miraldo M
    J Health Econ; 2009 Jan; 28(1):176-97. PubMed ID: 19038465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical reference prices. How do they work in practice?
    Dickson M; Redwood H
    Pharmacoeconomics; 1998 Nov; 14(5):471-9. PubMed ID: 10344913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.